ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0100

Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases

Cristobal Pavez Perales1, Ana Quiles Rocher2, Elena Grau Garcia3, Marta De la Rubia Navarro1, Samuel Leal Rodriguez4, Roxana Gonzalez Mazario1, Jorge Juan Fragio Gil1, Cristina Alcañiz Escandell3, Jose Ivorra Cortes1, Inmaculada Chalmeta Verdejo1, Luis Gonzalez Puig5, Isabel Martinez Cordellat1, Rosa Negueroles Albuixech1, Jose Eloy Oller Rodriguez1, Francisco Miguel Ortiz Sanjuan4, Elvira Vicens Bernabeu4, Carmen Najera Herranz1, Ines Canovas Olmos1 and Jose Andres Roman Ivorra1, 1Rheumatology Department. HUP La Fe, Valencia, Spain, 2Medical School, UCV, Valencia, Valencia, Spain, 3Rheumatology Department. HUP La Fe, Valencia, Comunidad Valenciana, Spain, 4Rheumatology Department, HUP La Fe, Valencia, Spain, 5Rheumatology Department. HUP La Fe, Torrente ( Valencia), Spain

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Biologicals, Infection, Miscellaneous Rheumatic and Inflammatory Diseases, Spondylarthropathies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster I: Diagnosis and Testing

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatic diseases (RD) are at higher risk of latent tuberculosis infection (LTBI) reactivation. To detect and treat it before starting treatment, especially with biological therapies, decrease the reactivation risk. Diagnosis is carried out by the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs), IGRAs might be more specific and sensitive. We aim to analyze the concordance between QuantiFERON-TB Gold In-Tube (QTF) and TST for the diagnosis of LTBI in patients with rheumatic diseases.

Methods: A retrospective observational study was conducted including patients diagnosed with RD screened for LTBI with both TST and QTF (2014-2018). Demographical and clinical variables at screening and at follow-up were collected. The concordance between both tests has been estimated as categorical variables using Cohen´s Kappa test, considering “poor” if it is ≤ 0,20; “low” if 0,20 < k ≤ 0,40, “moderate” if 0,40 < k ≤ 0,60, “substantial” if 0,60 < k ≤ 0,80 and “optimal” if k > 0,80.

Results: 167 patients were included (57% women) with a mean age of 52±16 years. 42% of them had systemic autoimmune diseases, 22% spondyloarthropathies and 36% other RD. 2 had history of past active tuberculosis (TB). At the time of screening, 46.11% were treated with GC.

LTBI was diagnosed in 35 patients: 15 had both QTF and TST positive, 16 only QTF positive and 4 only TST positive. 12 from 31 QTF positive patients were treated with GC at the time of screening. 3 from 19 TST positive patients were treated with GC at the time of screening.

After LTBI screening 62 patients received biological treatment, 4 of them had both test positive, 6 only QTF positive and 2 only TST positive. 11 received LTBI treatment according to the hospital protocol (isoniazid for 6 to 9 months). 10 completed treatment, 1 did not because of intolerance and did not receive other treatment. 1 patient with only TST positive was considered a false positive and did not receive treatment. During follow-up no TB reactivation was reported.

23 patients with LBTI received treatment other than biological therapy during follow-up, of them 8 received LBTI treatment. There was no TB reactivation during follow up.

The Kappa concordance between QTF and TST was estimated: moderated in the whole sample, poor in the patients treated with GC at screening, and substantial when the patients treated with GC at screening were excluded. Results are shown in Table 1.

TOTAL SAMPLE

PATIENTS WITH GC AT LTBI SCREENING

PATIENTS WITHOUT GC AT LTBI SCREENING

Number of coincidences (p1)

147 (88.02%)

64 (83.12%)

83 (92.22%)

Number of randomly expected coincidences (pe)

124.1 (74.28%)

62.9 (81.73%)

61.8 (68.62%)

Kappa = p1- pe /1- pe 

0,534

0,117

0.752

IC 95%

(0.358-0.710)

(-0.154-0.305)

(0.579-0.926)

 Table 1. Kappa concordance between QTF and TST.

Conclusion: QTF seems to be the most appropriate LTBI screening test in patients with RD treated with GC. Screening and treatment of LTBI in patients with RD treated with or without biological agents was effective in reducing TB reactivation.


Disclosure: C. Pavez Perales, None; A. Quiles Rocher, None; E. Grau Garcia, None; M. De la Rubia Navarro, None; S. Leal Rodriguez, None; R. Gonzalez Mazario, None; J. Fragio Gil, None; C. Alcañiz Escandell, None; J. Ivorra Cortes, None; I. Chalmeta Verdejo, None; L. Gonzalez Puig, None; I. Martinez Cordellat, None; R. Negueroles Albuixech, None; J. Oller Rodriguez, None; F. Ortiz Sanjuan, None; E. Vicens Bernabeu, None; C. Najera Herranz, None; I. Canovas Olmos, None; J. Roman Ivorra, None.

To cite this abstract in AMA style:

Pavez Perales C, Quiles Rocher A, Grau Garcia E, De la Rubia Navarro M, Leal Rodriguez S, Gonzalez Mazario R, Fragio Gil J, Alcañiz Escandell C, Ivorra Cortes J, Chalmeta Verdejo I, Gonzalez Puig L, Martinez Cordellat I, Negueroles Albuixech R, Oller Rodriguez J, Ortiz Sanjuan F, Vicens Bernabeu E, Najera Herranz C, Canovas Olmos I, Roman Ivorra J. Concordance Between the QuantiFERON-TB Gold In-Tube and Tuberculin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/concordance-between-the-quantiferon-tb-gold-in-tube-and-tuberculin-test-for-the-diagnosis-of-latent-tuberculosis-infection-in-patients-with-rheumatic-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/concordance-between-the-quantiferon-tb-gold-in-tube-and-tuberculin-test-for-the-diagnosis-of-latent-tuberculosis-infection-in-patients-with-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology